Immunogenic oxidized low-density lipoprotein/β2-glycoprotein I complexes in the diagnostic management of atherosclerosis

Clinical Reviews in Allergy and Immunology

Volumn 37, Issue 1, 2009, Pages 12-19

  Lopez, Luis R ^a   Kobayashi, Kazuko ^b   Matsunami, Yukana ^b   Matsuura, Eiji ^b  

^a Division of Medicine   (United States)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Antiphospholipid antibodies; Atherosclerosis; Autoimmunity; Oxidized LDL; 2GPI

Indexed keywords

BETA2 GLYCOPROTEIN 1; DIAGNOSTIC AGENT; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; AUTOIMMUNITY; BLOOD; FOAM CELL; HUMAN; IMMUNOLOGY; MACROPHAGE; METABOLISM; REVIEW;

ATHEROSCLEROSIS; AUTOIMMUNITY; BETA 2-GLYCOPROTEIN I; FOAM CELLS; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES;

EID: 70350436671     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-008-8096-8     Document Type: Review

References (67)

1. Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G (1997) Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus: a meta analysis. Lupus 6:467-473 (Pubitemid 27395386)
2. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, Stampfer MJ (1992) Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 117:997-1002
3. Hughes GRV, Harris EN, Gharavi AE (1986) The anticardiolipin syndrome. J Rheumatol 13:486-489
4. Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, Hughes GRV (1983) Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 2:1211-1214 (Pubitemid 14229783)
5. Harris EN, Chan JKH, Asherson RA, Hughes GRV (1986) Thrombosis, recurrent fetal loss and thrombocytopenia - predictive value of the anticardiolipin antibody test. Arch Intern Med 146:2153-2156 (Pubitemid 17189088)
6. Shah NM, Khamashta MA, Atsumi T, Hughes GR (1998) Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus 7:3-6 (Pubitemid 28052654)
7. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV (1995) The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332:993-997
8. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Euro-Phospholipid Project Group et al (2002) Antiphospholipid syndrome. Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019-1027 (Pubitemid 34303815)
9. Ward MM (1999) Premature morbidity from cardiovascular and cerebrovascular diseases in womenwith systemic lupus erythematosus. Arthritis Rheum 42:338-436
10. Aranow C, Ginzler EM (2000) Epidemiology of cardiovascular disease in systemic lupus erythematosus. Lupus 9:166-169 (Pubitemid 30199257)
11. Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A et al (2003) Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 62:1071-1077 (Pubitemid 37323571)
12. Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP, Kuller LH (1999) Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 42:51-60 (Pubitemid 29042570)
13. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R et al (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349:2399-2406 (Pubitemid 37542988)
14. Schattner A, Liang MH (2003) The cardiovascular burden of lupus; a complex challenge. Arch Intern Med 163:1507-1510 (Pubitemid 36835093)
15. American Heart Association, Heart Disease and Stroke Statistics - 2005 Update. http://www.americanheart.org
16. Ross R (1999) Atherosclerosis: an inflammatory disease. N Engl J Med 340:115-126
17. Virella G, Atchley DH, Koskinen S, Zheng D, Lopes-Virella M (2002) Pro-atherogenic and pro-inflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL. Clin Immunol 105:81-92 (Pubitemid 35222245)
18. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R et al (1992) Autoantibodies against oxidized LDL and progression of carotid atherosclerosis. Lancet 339:883-887
19. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Cote R, Grover SA, Fortin PR, Clarke AE, Senecal JL (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44:2331-2337 (Pubitemid 32977500)
20. Thomas RH (2001) Hypercoagulability syndromes. Arch Intern Med 161:2433-2439
21. Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T (1994) Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen-modified solid phase surface. J Exp Med 179:457-462 (Pubitemid 24058733)
22. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA (1990) Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 87:4120-4124
23. Brey RL, Abbott RD, Curb JD, Sharp DS, Ross GW, Stallworth CL, Kittner SJ (2001) β2-glycoprotein I dependent anticardiolipin antibodies and the risk of ischemic stroke and myocardial infarction. Stroke 32:1701-1706 (Pubitemid 32772193)
24. Lopez LR, Dier KJ, Lopez D, Merrill JT, Fink CA (2004) Anti-β2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Am J Clin Pathol 121:142-149 (Pubitemid 38090165)
25. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S et al (1989) Evidence for presence of oxidatively modified low-density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 85:1086-1095 (Pubitemid 19247577)
26. George J, Harats D, Gilburd B, Afek A, Levy Y, Schneiderman J et al (1999) Immunolocalization of β2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 99:2227-2230 (Pubitemid 29201126)
27. George J, Harats D, Gilburd B, Afek A, Shaish A, Kopolovic J, Shoenfeld Y (2000) Adoptive transfer of B2-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation 102:1822-1827
28. Ames PRJ, Alves J, Murat I, Isenberg DA, Nourooz-Zadeh J (1999) Oxidative stress in systemic lupus erythematosus and allied conditions with vascular involvement. Rheumatology 38:529-534 (Pubitemid 29504838)
29. Pratico D, Ferro D, Iuliano L, Rokach J, Conti F, Valesini G, Fitzgerald GA, Violi F (1999) Ongoing prothrombotic state in patients with antiphospholipid antibodies: a role for increased lipid peroxidation. Blood 93:3401-3407 (Pubitemid 29220907)
30. Ames PRJ, Tommasino C, Alves J, Morrow JD, Iannaccone L, Fossati G, Caruso S, Caccavo F, Brancaccio V (2000) Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: a pilot study. Lupus 9:688-695 (Pubitemid 32011795)
31. Morgan PE, Sturgess AD, Davies M (2005) Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus. Arthritis Rheum 52:2869-2879
32. Frostegard J, Svenungsson E, Wu R, Gunnarsson I, Lundberg IE, Klareskog L et al (2005) Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 52:192-200 (Pubitemid 40129248)
33. Rose N, Afanasyeva M (2003) Autoimmunity: busting the atheorsclerotic plaque. Nat Med 9:641-642
34. McMurray HF, Parthasarathy S, Steinberg D (1993) Oxidatively modified low-density lipoprotein is a chemoattractant for human T lymphocytes. J Clin Invest 92:1004-1008 (Pubitemid 23262425)
35. Fong LG, Parthasarathy S, Witztum JL, Steinberg D (1987) Nonenzymatic oxidative cleavage of peptide bonds in apoprotein B-100. J Lipid Res 28:1466-1477 (Pubitemid 18025879)
36. Esterbauer H, Jurgens G, Quehenberger O, Koller E (1987) Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J Lipid Res 28:495-509 (Pubitemid 17116184)
37. Itabe H, Takeshima E, Iwasaki H, Kimura J, Yoshida Y, Imanaka T et al (1994) A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phsophatidylcholine and polypeptides. J Biol Chem 269:15274-15279
38. Friedman P, Horkko S, Steinberg D (2001) Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids: importance of Schiff base formation and Aldol condensation. J Biol Chem 277:7010-7020 (Pubitemid 34953088)
39. Anuurad E, Boffa MB, Koschinsky ML, Berglund L (2006) Lipoprotein (a): a unique risk factor for cardiovascular disease. Clin Lab Med 26:751-772 (Pubitemid 44716507)
40. Danesh J, Collins R, Petro R (2000) Lipoprotein (a) and coronary heart disease. Meta-analoysis of prospective studies. Circulation 102:1082-1085
41. Tsimikas S, Witztum JL (2008) The role of oxidized phsopholipids in mediating lipoprotein (a) atherogenicity. Curr Opin Lipid 19:369-377
42. Roubey RA (1994) Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 84:2854-2867
43. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, Van Breda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM (1990) Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335:1544-1547 (Pubitemid 20189625)
44. Sheng Y, Kandiah DA, Krilis SA (1998) β2-glycoprotein I: Target antigen for 'antiphospholipid ' antibodies. Immunological and molecular aspects. Lupus 7:S5-S9 (Pubitemid 28484571)
45. Vaarala O (1996) Antiphospholipid antibodies and atherosclerosis. Lupus 5:442-447
46. Vaarala O (1998) Antiphospholipid antibodies in myocardial infarction. Lupus 7:S132-s134
47. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T (1993) Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 341:923-925 (Pubitemid 23109111)
48. Steinberg D (1997) Low-density lipoprotein oxidation and its pathobiological significance. J Biol Chem 272:20963-20966
49. Heinecke JW (1997) Mechanisms of oxidative damage of low-density lipoprotein in human atherosclerosis. Curr Opin Lipid 8:268-274
50. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T (1997) Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 107:569-573 (Pubitemid 27102148)
51. Kobayashi K, Matsuura E, Liu Q, Furukawa J, Kaihara K, Inagaki J, Atsumi T et al (2001) A specific ligand for β2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J Lipid Res 42:697-709 (Pubitemid 32507169)
52. Liu Q, Kobayashi K, Inagaki J, Sakairi N, Iwado A, Yasuda T, Koike T, Voelker DR, Matsuura E (2002) ω-carboxyl variants of 7-ketocholesteryl esters are ligands for β2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages. J Lipid Res 43:1486-1495
53. Matsuura E, Kobayashi K, Koike T, Shoenfeld Y, Khamashta MA, Hughes GRV (2003) Oxidized low-density lipoprotein as a risk factor of thrombosis in antiphospholipid syndrome. Lupus 12:550-554 (Pubitemid 36890149)
54. Kobayashi K, Kishi M, Atsumi T, Bertolaccini ML, Makino H, Sakairi N et al (2003) Circulating oxidized LDL forms complexes with β 2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res 44:716-726 (Pubitemid 37279673)
55. Maiti SN, Balasubramanian K, Ramoth JA, Shroit AJ (2008) Beta-2 glycoprotein I-dependent macrophage uptake of apoptotic cells. Binding to lipoprotein receptor-related protein receptor family members. J Biol Chem 283:3761-3766
56. Lopez LR, Hurley BL, Simpson DF, Matsuura E (2005) Oxidized low-density lipoprotein/B2-glycoprotein I complexes in type 2 diabetes mellitus. Ann N Y Acad Sci 1051:97-103
57. Kasahara J, Kobayashi K, Maeshima Y, Yamasaki Y, Yasuda T, Matsuura E, Makino H (2004) Clinical significance of serum oxidized low-density lipoprotein/B2-glycoprotein I complexes in patients with chronic renal diseases. Nephron Clin Practice 98:15-24
58. Matsuura E, Kobayashi K, Inoue K, Lopez LR, Schoenfeld Y (2005) Oxidized LDL/B2-glycoprotein I complexes: new aspects in atherosclerosis. Lupus 14:736-741 (Pubitemid 41413302)
59. Lopez LR, Simpson DF, Hurley BL, Matsuura E (2005) OxLDL/β2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement. Ann N Y Acad Sci 1051:313-322 (Pubitemid 41362761)
60. Lopez D, Garcia-Valladares I, Palafox-Sanchez C, Garcia De La Torre I, Kobayashi K, Matsuura E, Lopez LR (2004) Oxidized low-density lipoprotein/β2-glycoprotein I complexes and autoantibodies to oxLig-1/β2-glycoprotein I in patients with systemic lupus erythematosus and antiphospholipid syndrome. Am J Clin Pathol 121:426-436 (Pubitemid 38298177)
61. Lopez D, Kobayashi K, Merrill JT, Matsuura E, Lopez LR (2003) IgG Autoantibodies against β2-glycoprotein I complexed with a lipid ligand derived from oxidized low-density lipoprotein are associated with arterial thrombosis in antiphospholipid syndrome. Clin Dev Immunol 10:203-211 (Pubitemid 38089413)
62. Bassi N, Ghirardello A, Iaccarino L, Zampieri S, Arienti S, Rampudda ME, Shoenfeld Y, Doria A (2006) OxLDL/β2GPI, anti-oxLDL/β2GPI complex and atherosclerosis in SLE patients. Autoimmun Rev (Elsevier), Editors Shoenfeld & Gershwin, Abstracts of the 5th International Congress on Autoimmunity, Sorrento, Italy, pp 19-20
63. Pengo V, Bison E, Ruffatti A, Iliceto S (2008) Antibodies to oxidized LDL/β2-glycoprotein I in antiphospholipid syndrome patients with venous and arterial thromboembolism. Thromb Res doi:10.1016/j.thromres.2007.12.028 (on line)
64. Matsuura E, Lopez LR (2004) Are oxidized LDL/β2-glycoprotein I complexes pathogenic antigens in autoimmune-mediated atherosclerosis? Clin Dev Immunol 11:103-111 (Pubitemid 38955066)
65. Kobayashi K, Lopez LR, Shoenfeld Y, Matsuura E (2005) The role of innate and adaptive immunity to oxidized low-density lipoprotein in the development of atherosclerosis. Ann N Y Acad Sci 1051:442-454 (Pubitemid 41362774)
66. Lopez LR, Salazar-Paramo M, Palafox-Sanchez C, Hurley BL, Matsuura E, Garcia De La Torre I (2006) Oxidized low-density lipoprotein and B2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis. Lupus 15:80-86 (Pubitemid 43345332)
67. Greco TP, Conti-Kelly AM, Matsuura E, Greco T Jr, Dier KJ, Svanas G, Doyle R, Lopez LR (2007) Antiphospholipid antibodies in patients with coronary artery disease. New cardiac risk factors? Ann N Y Acad Sci 1108:466-474 (Pubitemid 47528760)